Advances in chemotherapy, including anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), anti-vascular endothelial growth factor (VEGF) TKIs, inhibitors of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 kinase, or immune checkpoint inhibitors (ICIs) for metastatic colorectal cancers (CRCs), have provided benefits such as improvement in overall survival (OS) or progression-free survival (PFS) of patients over the past decade; however, there are still many cancers that are unresponsive or develop chemoresistance [1]. Here, BRAF is linked to cancer.